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Abstract 
 
The 2-unsubstituted imidazole N-oxides with a 3,3,3-trifluoro-2-hydroxypropyl group at 
N(1) in the presence of acetic anhydride undergo cyclization via the intramolecular 
nucleophilic attack of the hydroxyl group onto C(2) of the imidazole ring to give 
trifluoromethylated derivatives of 2,3-dihydroimidazo[2,1-b]oxazoles. This method, starting 
with enantiopure substrates, allows the preparation of enantiopure products in a one-pot 
procedure.  
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1. Introduction 
 
The 2-unsubstituted imidazole N-oxides of type 1 (imidazole 3-oxides), constitute a class 
of imidazole derivatives, which can be considered as useful starting materials for the 
preparation of more complex imidazole derivatives [1]. They are conveniently accessible by 
condensation of N-substituted formaldimines with the corresponding α-hydroxy 
iminoketones. In terms of the reactivity, N-oxides 1 resemble aldonitrones, and therefore react 
with diverse dipolarophiles via a [3+2]-cycloaddition as the initial step of the conversion. For 
example, fluoroalkylated imidazole 2 can be obtained from 1a and perfluoropropene after 
elimination of fluorophosgene from the initially formed [3+2]-cycloadduct 3 (Scheme 1) [2]. 
 
 
 
Scheme 1. Fluoroalkylation of an imidazole N-oxide via [3+2]-cycloaddition [2]. 
 
Another important conversion of N-oxides 1 is the rearrangement into isomeric 
imidazole-2-ones by treatment with acetic anhydride [3]. However, in the case of 1 bearing a 
β-hydroxyalkyl residue at N(1), the reaction with acetic anhydride leads to the intramolecular 
ring closure, and imidazo[2,1-b]oxazole derivatives are formed as final products [4]. In a 
recent publication, we reported on a similar ring closure via a nucleophilic attack of an amino 
group [5]. 
The aim of the present study was the synthesis of 2-trifluoromethyl-substituted 
imidazo[2,1-b]oxazoles via the acetic anhydride-initiated cyclization of selected 1-(3,3,3-
trifluoro-2-hydroxypropyl)imidazole 3-oxides, especially of enantiopure substrates.  
 
2. Results and discussion 
 
In a recent publication, the synthesis of optically active imidazole N-oxides bearing a 
fluorinated hydroxyalkyl group at N(1) was described [6]. The preparation of the new series 
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of compounds 7 (Table 1) is presented in Scheme 2. In the first step, racemic or enantiopure 
β-amino alcohols 4 were treated with paraformaldehyde to give the corresponding 
formaldimines 5. Subsequently, the latter were treated with α-hydroxy iminoketones 6 in 
boiling ethanol affording the desired products 7. Starting with enantiopure substrates 4, 
optically pure imidazole N-oxides 7 were obtained. Their enantiopurity was confirmed by 1H 
NMR spectroscopy using a chiral agent [7]. 
 
 
 
Scheme 2. Synthesis of 1-(3,3,3-trifluoro-2-hydroxypropyl)imidazole 3-oxides 6. 
 
In a typical experiment, the racemic imidazole N-oxide 7a in CH2Cl2 solution was treated 
with acetic anhydride in access at room temperature. The progress of the reaction was 
monitored by TLC, and after completion of the reaction, the crude product was analyzed by 
1H NMR and IR spectroscopy. 
The IR spectrum of the obtained compound did not show the expected absorption band 
for the imidazolone isomeric with 7a. Moreover, there were no absorption bands neither for 
hydroxyl nor ester groups detected. In the 1H NMR spectrum in CDCl3, the most 
characteristic feature was the presence of an AB system located at 4.83 and 4.50 ppm. 
Furthermore, the mass spectrum evidenced the formation of a product via elimination of water 
(m/z 407). 
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Table 1. Synthesis of imidazole 3-oxides 7 and their transformation into 2,3-
dihydroimidazo[2,1-b]oxazoles 8. 
 
7 R1 R2 X Yield [%] 8 Yield [%] 
(RS)-7a Ph Ph H 63 (RS)-8a 82 
(S)-7a    60 (S)-8a 79 
(R)-7a    59 (R)-8a 83 
(RS)-7b Ph Ph MeO 66 (RS)-8b 80 
(S)-7b    67 (S)-8b 85 
(R)-7b    69 (R)-8b 86 
(S)-7c Me Me MeO 71 (S)-8c 50 
(R)-7c    75 (R)-8c 49 
(S)-7d Me Ph MeO 65 (S)-8d 79 
(R)-7d    68 (R)-8d 80 
(S)-7e CONHPh Me H 59 (S)-8e 81 
(R)-7e    61 (R)-8e 83 
 
Based on these data, the structure of the imidazo[2,1-b]oxazole 8a was proposed (Scheme 
3). The 13C NMR spectrum of the purified sample fitted well with this proposal. For example, 
the characteristic signals for sp3-C-atoms C(2) and C(3) appeared at 92.1 and 51.2 ppm, 
respectively. 
 
 
 
Scheme 3. Reaction mechanism for the formation of 2,3-dihydroimidazo[2,1-b]oxazoles 8. 
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The same protocol was applied for the transformation of a series of enantiopure 
imidazole N-oxides 7, and in all cases were optically active products obtained in good yields 
(Table 1). 
The mechanistic explanation of the reaction pathway is presented in Scheme 3. The initial 
step of the multistep conversion is the formation of the reactive imidazolium cation 9, with 
undergoes a cyclization via the nucleophilic attack of the OH-group onto the imidazolium 
C(2)-atom leading to the 1,3-oxazolidine ring of the bicyclic compound 10. Apparently, this 
ring closure occurs faster than both the rearrangement to the imidazolone derivative [3] and 
the competitive acylation of the hydroxyl group [8]. Finally, elimination of AcOH leads to the 
bicyclic product 10. All steps of the presented reaction occur with preservation of the 
configuration of the stereogenic centre.  
 
3. Conclusion 
 
The results of the present study show that the 2-unsubstituted imidazole N-oxides 7 
bearing a fluorinated 2-hydroxalkyl group at N(1) can be efficiently transformed into hitherto 
unknown, trifluoromethyl-substituted imidazo[2,1-b]oxazole derivatives 8. The starting 
materials 7 can be easily prepared in enantiopure form and, therefore, optically active 
products of type 8 are also accessible. It is well established that fluoroalkyl-substituted 
heterocycles found diverse applications, and for that imidazo[2,1-b]oxazole reason, products 
8 are of potential interest in organic synthesis, medicinal chemistry and related fields [9]. The 
novel approach to this fused heterocyclic scaffold via properly substituted imidazole N-oxides 
supplements the earlier reported methods for their preparation based, e.g. on heterocylization 
of an imidazolone equivalent [10], reaction of dinitroimidazole with substituted oxiranes [11] 
or copper(I) catalyzed intramolecular alkoxylation of imidazoles [12].  
Differently substituted imidazo[2,1-b]oxazoles display not only antibacterial and 
antitubercular activity [13] but they are also known as radiosensitizing agents [14]. In a very 
recent publication a series of trisubstituted imidazo[2,1-b]oxazoles, including fluorinated 
derivatives, has been described and the results of the study on their biological activities (new 
drug candidates for visceral leishmaniasis) were presented and discussed [15]. 
 
Acknowledgments 
 
	   6	  
G. M. and A. W. thank the National Science Center (Cracow) for financial support 
(Grants: OPUS-7 # UMO-2014/13/B/ST5/04004, and PRELUDIUM # UMO-
2012/07/N/ST5/01873). Registration of the HR-ESI-MS spectra by PD Dr. L. Bigler, 
University of Zurich, is acknowledged.  
 
4. Experimental part 
 
4.1. General experimental procedures 
 
 Melting points were determined in a capillary using a Mel-Temp II (Aldrich) or 
STUART SMP30 apparatus and are uncorrected. The IR Spectra were recorded on a NEXUS 
FT-IR spectrophotometer in KBr; absorptions (ν) in cm–1. The 1H, 13C{1H}, and 19F NMR 
spectra were measured on a Bruker Avance III instrument (600, 150, and 565 MHz, resp.) in 
CD3OD, DMSO-d6 or CDCl3 using solvent signals as reference. The multiplicity of signals in 
the 13C NMR spectra was established using the HMQC technique. Chemical shifts (δ) are 
given in ppm and coupling constants J in Hz. Assignments of signals in 13C NMR spectra 
were made on the basis of HMQC experiments. HR-ESI-MS: Bruker maxis spectrometer; 
ESI-MS: Varian 500. Optical rotations were determined on a PERKIN–ELMER 241 MC 
polarimeter for λ = 589 nm. All chromatographic separations were carried out on a column 
packed with silica gel.  
 
4.2. General procedure for the synthesis of imidazole N-oxides 7 
 
To the solution of β-amino-α-trifluoromethyl alcohol 4 (1.0 mmol) in MeOH (3 ml) 
paraformaldehyde (1.0 mmol) was added at room temperature and the mixture was stirred 
overnight. Then, the solvent was evaporated and the obtained imine was dissolved in EtOH (4 
ml). To this solution, an equimolar amount of the corresponding α-hydroxyimino ketone was 
added and the mixture was reflux for 3 h. Next, the solvent was removed under reduced 
pressure and the resulting residue was purified by column chromatography (AcOEt/MeOH, 
8:2). 
3-(4,5-Diphenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-phenylpropan-2-ol ((R,S)-
7a). Yield: 0.267 g (63%). Colorless crystals. Mp. 198–200 °C. IR (KBr): ν 3700–2000vs,br. 
with intense bands at 3420br, 3181m, 3061m; 1505m, 1489m, 1447s, 1404m, 1352s, 1270s, 
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1159s.br, 1052m, 864m, 760s, 699s, 652s, 513m. 1H NMR (CD3OD): δ 8.28 (s, 1H, HC(2)); 
7.42–7.38 (m, 1H, HC(arom)); 7.34–7.29 (m, 3H, HC(arom)); 7.27–7.18 (m, 9H, HC(arom)); 
6.93–6.89 (m, 2H, HC(arom)); 4.56 (br s, 2H, H2C). 13C NMR (CD3OD): δ 134.4, 130.9, 
129.8, 129.4, 129.3, 129.0, 128.9, 128.8, 128.6, 128.4, 128.1, 127.7, 126.2, 126.0, 125.9 (15 
CH(arom), 3 C(arom), CH(imid), 2 C(imid)); 124.9 (q, 1JC,F = 284.9, CF3); 76.4 (q, 2JC,F = 
28.5, CCF3); 49.6 (CH2). 19F NMR (CD3OD): δ –78.2. HR-ESI-MS: 425.14712 (calcd 
425.14714 for C24H20O2N2F3, [M+H]+). 
 
(S)-3-(4,5-Diphenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-phenylpropan-2-ol ((S)-
7a). Yield: 0.254 g (60%). Colorless crystals. Mp. 150–152 °C. IR (KBr): ν 3700–2000vs,br. 
with intense bands at 3421br, 3170m, 3060m; 1447m, 1402w, 1351m, 1267s, 1162s.br, 
1053w, 864w, 761s, 699s, 651m, 513w. 1H NMR (CD3OD): δ 8.35 (s, 1H, HC(2)); 7.47–7.43 
(m, 1H, HC(arom)); 7.39–7.35 (m, 3H, HC(arom)); 7.31–7.24 (m, 9H, HC(arom)); 6.97–6.94 
(m, 2H, HC(arom)); 4.61 (br s, 2H, H2C). 13C NMR (CD3OD): δ 134.4, 130.9, 129.8, 129.4, 
129.3, 128.9, 128.8, 128.6, 128.4, 128.3, 128.1, 127.7, 126.2, 126.0, 125.9 (15 CH(arom), 3 
C(arom), CH(imid), 2 C(imid)); 125.0 (q, 1JC,F = 285.0, CF3); 76.4 (q, 2JC,F = 27.4, CCF3); 
49.6 (CH2). 19F NMR (CD3OD): δ –78.1. HR-ESI-MS: 425.14704 (calcd 425.14714 for 
C24H20O2N2F3, [M+H]+). [α]D25 = +60 (c 1.0, MeOH). 
 
(R)-3-(4,5-Diphenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-phenylpropan-2-ol ((R)-
7a). Yield: 0.250 g (59%). Colorless crystals. Mp. 138–140 °C. IR (KBr): ν 3700–2000vs,br. 
with intense bands at 3423br, 3170w, 3061w; 1447m, 1351m, 1267s, 1162s.br, 1053w, 864w, 
761s, 700s, 651m, 513w. 1H NMR (CDCl3): δ 8.62 (s, 1H, HC(2)); 7.35–7.31 (m, 1H, 
HC(arom)); 7.24–7.20 (m, 2H, HC(arom)); 7.18–7.15 (m, 3H, HC(arom)); 7.09–6.97 (m, 7H, 
HC(arom)); 6.72–6.68 (m, 2H, HC(arom)); 4.43, 4.38 (AB, JA,B = 13.8, 2H, H2C). 13C NMR 
(CDCl3): δ 134.4, 130.9, 129.8, 129.4, 129.3, 128.9, 128.7, 128.5, 128.4, 128.2, 128.1, 127.7, 
126.2, 126.0, 125.9 (15 CH(arom), 3 C(arom), CH(imid), 2 C(imid)); 124.9 (q, 1JC,F = 286.2, 
CF3); 76.4 (q, 2JC,F = 28.0, CCF3); 49.6 (CH2). 19F NMR (CDCl3): δ –76.8. HR-ESI-MS: 
425.14709 (calcd 425.14714 for C24H20O2N2F3, [M+H]+). [α]D25 = –62 (c 1.0, MeOH). 
 
3-(4,5-Diphenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-methoxyphenyl)propan-
2-ol ((RS)-7b). Yield: 0.299 g (66%). Colorless crystals. Mp. 186–188 °C. IR (KBr): ν 3600–
2700vs,br. with intense bands at 3420br, 3177w, 3058w, 2958w, 2839w; 1612s, 1515s, 
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1445s, 1351s, 1258s, 1159br. s, 1028m, 977w, 830m, 762s, 701s, 651s. 1H NMR (CDCl3): δ 
8.78 (s, 1H, HC(2)); 7.45–7.41 (m, 1H, HC(arom)); 7.37–7.33 (m, 2H, HC(arom)); 7.25–7.11 
(m, 7H, HC(arom)); 6.94–6.89 (m, 2H, HC(arom)); 6.72–6.68 (m, 2H, HC(arom)); 4.56, 4.38 
(AB, JA,B = 13.8, 2H, H2C); 3.75 (s, 3H, H3C). 13C NMR (CDCl3): δ 159.8, 131.0, 130.1, 
129.5, 129.0, 128.9, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 126.8, 126.3, 113.8 (14 
CH(arom), 4 C(arom), CH(imid), 2 C(imid)); 125.4 (q, 1JC,F = 286.3, CF3); 76.2 (q, 2JC,F = 
27.9, CCF3); 54.9 (CH3); 50.3 (CH2). 19F NMR (CDCl3): δ –78.8. HR-ESI-MS: 455.15771 
(calcd 455.15770 for C25H22O3N2F3, [M+H]+). 
 
(S)-3-(4,5-Diphenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-
methoxyphenyl)propan-2-ol ((S)-7b). Yield: 0.304 g (67%). Colorless crystals. Mp. 196–198 
°C. IR (KBr): ν 3600–2500vs,br. with intense bands at 3423br, 3171w, 3058w, 2959w, 
2839w; 1612m, 1515s, 1445m, 1351m, 1257s, 1173br. s, 1029w, 830w, 763m, 700m, 651m. 
1H NMR (CD3OD): δ 8.26 (s, 1H, HC(2)); 7.41–7.37 (m, 1H, HC(arom)); 7.33–7.29 (m, 2H, 
HC(arom)); 7.26–7.18 (m, 5H, HC(arom)); 7.12–7.08 (m, 2H, HC(arom)); 6.95–6.91 (m, 2H, 
HC(arom)); 6.78–6.74 (m, 2H, HC(arom)); 4.53 (br s, 2H, H2C); 3.73 (s, 3H, H3C). 13C NMR 
(CD3OD): δ 160.3, 130.8, 129.8, 129.4, 129.0, 128.9, 128.6, 128.4, 128.2, 127.7, 127.2, 
126.3, 126.1, 126.0, 113.7 (14 CH(arom), 4 C(arom), CH(imid), 2 C(imid)); 125.1 (q, 1JC,F = 
284.9, CF3); 76.2 (q, 2JC,F = 27.7, CCF3); 54.5 (CH2); 49.7 (CH3). 19F NMR (CD3OD): δ –
77.3. HR-ESI-MS: 455.15752 (calcd 455.15770 for C25H22O3N2F3, [M+H]+). [α]D25 = +53 (c 
1.0, MeOH). 
 
(R)-3-(4,5-Diphenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-
methoxyphenyl)propan-2-ol ((R)-7b). Yield: 0.313 g (69%). Colorless crystals. Mp. 204–206 
°C. IR (KBr): ν 3600–2200vs,br. with intense bands at 3424br, 3193m, 3060w, 2960w, 
2839w; 1611m, 1516s, 1445m, 1350m, 1258s, 1173br. s, 1030m, 833m, 763s, 699s, 650m. 1H 
NMR (CD3OD): δ 8.25 (s, 1H, HC(2)); 7.39–7.34 (m, 1H, HC(arom)); 7.31–7.27 (m, 2H, 
HC(arom)); 7.24–7.16 (m, 5H, HC(arom)); 7.11–7.07 (m, 2H, HC(arom)); 6.93–6.89 (m, 2H, 
HC(arom)); 6.76–6.72 (m, 2H, HC(arom)); 4.50 (br s, 2H, H2C); 3.71 (s, 3H, H3C). 13C NMR 
(CD3OD): δ 160.3, 130.8, 129.8, 129.4, 128.9, 128.8, 128.6, 128.4, 128.2, 127.7, 127.2, 
126.3, 126.1, 126.0, 113.7 (14 CH(arom), 4 C(arom), CH(imid), 2 C(imid)); 125.1 (q, 1JC,F = 
285.2, CF3); 76.2 (q, 2JC,F = 27.7 CCF3); 54.5 (CH2); 49.7 (CH3). 19F NMR (CD3OD): δ –78.4. 
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HR-ESI-MS: 455.15759 (calcd 455.15770 for C25H22O3N2F3, [M+H]+). [α]D25 = –50 (c 1.0, 
MeOH). 
 
(S)-3-(4,5-Dimethyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-
methoxyphenyl)propan-2-ol ((S)-7c). Yield: 0.219 g (73 %). Colorless crystals, Mp. 232–235 
°C (lit. [6], Mp. 234–236 °C(decomp.)). 
 
(R)-3-(4,5-Dimethyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-
methoxyphenyl)propan-2-ol ((R)-7c). Yield: 0.247 g (75%). Colorless crystals. Mp. 222–224 
°C. IR (KBr): ν 3600–2000vs,br. with intense bands at 3451br, 3186m, 2960w, 2934w, 
2837w; 1612m, 1514s, 1457m, 1386m, 1262br. s, 1154br. s, 1086s, 967m, 830s, 753m, 659s. 
1H NMR (CD3OD): δ 7.68 (s, 1H, HC(2)); 7.41–7.37 (m, 2H, HC(arom)); 6.91–6.87 (m, 2H, 
HC(arom)); 4.44 (br s, 2H, H2C); 3.75 (s, 3H, H3C); 1.99 (s, 3H, H3C); 1.92 (s, 3H, H3C). 13C 
NMR (CD3OD): δ 160.4, 127.5, 126.6, 126.5, 124.8, 123.7, 113.6 (4 CH(arom), 2 C(arom), 
CH(imid), 2 C(imid)); 125.3 (q, 1JC,F = 284.9, CF3); 76.5 (q, 2JC,F = 27.6, CCF3); 54.4 (CH2); 
49.6 (CH3); 7.2 (CH3); 5.6 (CH3). 19F NMR (CD3OD): δ –78.2. HR-ESI-MS: 331.12620 
(calcd 331.12640 for C15H18O3N2F3, [M+H]+). [α]D25 = –21 (c 1.0, MeOH). 
 
(S)-3-(5-Methyl-4-phenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-
methoxyphenyl)propan-2-ol ((S)-7d). Yield: 0.255 g (65%). Colorless crystals. Mp. 88–90 °C. 
IR (KBr): ν 3600–2000vs,br. with intense bands at 3416br, 3060m, 2976m, 2865w; 1624w, 
1498m, 1448m, 1402m, 1352s, 1267br. s, 1154br. s, 1028m, 971w, 765s, 698s, 656m. 1H 
NMR (CD3OD): δ 8.11 (s, 1H, HC(2)); 7.48–7.41 (m, 3H, HC(arom)); 7.06–7.02 (m, 4H, 
HC(arom)); 6.75–6.71 (m, 2H, HC(arom)); 4.52, 4.46 (AB, JAB = 14.4, 2H, H2C); 3.76 (s, 3H, 
H3C); 1.97 (s, 3H, H3C). 13C NMR (CD3OD): δ 160.2, 130.2, 129.3, 128.7, 128.1, 127.4, 
127.2, 126.4, 126.3, 125.9, 113.6 (9 CH(arom), 3 C(arom), CH(imid), 2 C(imid)); 125.0 (q, 
1JC,F = 285.2, CF3); 76.1 (q, 2JC,F = 27.8, CCF3); 54.4 (CH3); 49.6 (CH2); 6.1 (CH3). 19F NMR 
(CD3OD): δ –78.7. HR-ESI-MS: 393.14186 (calcd 393.14205 for C20H20O3N2F3, [M+H]+). 
[α]D
25 = +70 (c 1.0, MeOH). 
 
(R)-3-(5-Methyl-4-phenyl-3-oxido-1H-imidazol-1-yl)-1,1,1-trifluoro-2-(4-
methoxyphenyl)propan-2-ol ((R)-7d). Yield: 0.266 g (68%). Pale yellow oil. IR (film): ν 
3600–2200vs,br. with intense bands at 3423br, 3060w, 2865w; 1623w, 1498w, 1448w, 
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1401w, 1351m, 1267br. s, 1154br. s, 1028w, 971w, 765s, 698s, 656m. 1H NMR (CD3OD): δ 
8.04 (s, 1H, HC(2)); 7.39–7.34 (m, 3H, HC(arom)); 6.99–6.95 (m, 4H, HC(arom)); 6.68–6.64 
(m, 2H, HC(arom)); 4.45, 4.39 (AB, JAB = 14.6, 2H, H2C); 3.69 (s, 3H, H3C); 1.90 (s, 3H, 
H3C). 13C NMR (CD3OD): δ 160.2, 130.2, 129.2, 128.7, 128.0, 127.4, 127.2, 126.4, 126.3, 
125.9, 113.6 (9 CH(arom), 3 C(arom), CH(imid), 2 C(imid)); 125.1 (q, 1JC,F = 285.3, CF3); 
76.1 (q, 2JC,F = 27.5, CCF3); 54.4 (CH3); 49.6 (CH2); 6.1 (CH3). 19F NMR (CD3OD): δ –77.1. 
HR-ESI-MS: 393.14213 (calcd 393.14205 for C20H20O3N2F3, [M+H]+). [α]D25 = –69 (c 1.0, 
MeOH). 
	  
(S)-5-Methyl-3-oxy-1-(3,3,3-trifluoro-2-hydroxy-2-phenylpropyl)-1H-imidazole-4-
carboxylic acid phenylamide ((S)-7e). Yield: 0.239 g (59%). Colorless crystals. Mp. 264–266 
°C. IR (KBr): ν 3600–2500vs,br. with intense bands at 3247br, 3109m, 3044s, 2966m; 1681s, 
1618s, 1592s, 1564s, 1448s, 1315s, 1269s, 1164s, 1024m, 977m, 760s, 702s, 630s. 1H NMR 
(DMSO-d6): δ 13.40 (s, 1H, NH); 8.07 (s, 1H, HC(2)); 7.62–7.55 (m, 4H, HC(arom)); 7.48–
7.42 (m, 3H, HC(arom)); 7.35–7.30 (m, 2H, HC(arom)); 7.10–7.06 (m, 1H, HC(arom)); 4.69, 
4.65 (AB, JAB = 15.0, 2H, H2C); 2.34 (s, 3H, H3C). 13C NMR (DMSO-d6): δ 157.7 (C=O); 
138.6, 135.3, 133.3, 129.8, 129.5, 129.0, 127.6, 126.9, 124.1, 120.1, 119.9 (10 CH(arom), 2 
C(arom), CH(imid), 2 C(imid)); 125.6 (q, 1JC,F = 286.2, CF3); 76.6 (q, 2JC,F = 26.9, CCF3); 
49.3 (CH2); 9.8 (CH3). 19F NMR (DMSO-d6): δ –76.3. HR-ESI-MS: 406.13666 (calcd 
406.13730 for C20H19O3N3F3, [M+H]+). [α]D25 = +21 (c 1.0, MeOH). 
 
(R)-5-Methyl-3-oxy-1-(3,3,3-trifluoro-2-hydroxy-2-phenylpropyl)-1H-imidazole-4-
carboxylic acid phenylamide ((R)-7e). Yield: 0.247 g (61%). Colorless crystals. Mp. 258–260 
°C. IR (KBr): ν 3600–2600vs,br. with intense bands at 3248br, 3109m, 3044m, 2966m; 
1681s, 1618s, 1592s, 1564s, 1501m, 1448m, 1315s, 1269s, 1204s, 1157s, 1024m, 977m, 
760s, 702s, 630s. 1H NMR (DMSO-d6): δ 13.40 (s, 1H, NH); 8.07 (s, 1H, HC(2)); 7.63–7.56 
(m, 4H, HC(arom)); 7.48–7.45 (m, 3H, HC(arom)); 7.35–7.30 (m, 2H, HC(arom)); 7.10–7.06 
(m, 1H, HC(arom)); 4.69, 4.66 (AB, JAB = 15.0, 2H, H2C); 2.35 (s, 3H, H3C). 13C NMR 
(DMSO-d6): δ 157.1 (C=O); 138.0, 134.8, 132.8, 129.2, 129.0, 128.5, 127.0, 126.4, 123.6, 
119.5, 119.4 (10 CH(arom), 2 C(arom), CH(imid), 2 C(imid)); 125.0 (q, 1JC,F = 285.6, CF3); 
76.0 (q, 2JC,F = 27.3, CCF3); 48.8 (CH2); 9.3 (CH3). 19F NMR (DMSO-d6): δ –75.6. HR-ESI-
MS: 406.13704 (calcd 406.13730 for C20H19O3N3F3, [M+H]+). [α]D25 = –23 (c 1.0, MeOH). 
 
	   11	  
4.3. General procedure for the synthesis of trifluoromethylated 2,3-dihydroimidazo[1,3-
oxazole] derivatives 8. 
 
To a solution of the corresponding imidazole N-oxide 7 (1 mmol) in CH2Cl2 (5 ml), 
freshly distilled acetic anhydride (10 ml) was added at room temperature. After all of 7 was 
consumed (monitored by TLC), MeOH (5 ml) was added to the mixture and stirring was 
continued for 30 min. Next, the solvent was evaporated and the crude product was purified by 
column chromatography (hexane/AcOEt, 7:3). 
 
2,5,6-Triphenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole ((R,S)-8a). Yield: 
0.332 g (82%). Colorless crystals. Mp. 152–154 °C. IR (KBr): ν 3060br.w, 1604s, 1587s, 
1570m, 1499s, 1343s, 1303s, 1204vs, 1191vs, 1170s, 1062s, 1006s, 974m, 774m, 700s. 1H 
NMR (CDCl3): δ 7.65–7.58 (m, 4H, HC(arom)); 7.53–7.49 (m, 3H, HC(arom)); 7.44–7.35 
(m, 5H, HC(arom)); 7.29–7.25 (m, 2H, HC(arom)); 7.24–7.20 (m, 1H, HC(arom)); 4.83, 4.50 
(AB, JAB = 10.2, 2H, H2C). 13C NMR (CDCl3): δ 157.3, 138.5, 134.5, 133.6, 130.3, 130.2, 
129.1, 129.0, 128.3, 128.2, 128.1, 127.2, 126.9, 126.0, 121.8 (15 CH(arom), 3 C(arom), 3 
C(imid)); 123.4 (q, 1JC,F = 282.5, CF3); 92.1 (q, 2JC,F = 31.1, CCF3); 51.2 (CH2). 19F NMR 
(CDCl3): δ –80.7. HR-ESI-MS: 407.13573 (calcd 407.13657 for C24H18ON2F3, [M+H]+). 
 
(S)-2,5,6-Triphenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole ((S)-8a). Yield: 
0.321 g (79%). Colorless oil. IR (film): ν 3062br.w, 2903w, 1606s, 1590s, 1572s, 1500s, 
1443m, 1340s, 1305s, 1197vs, 1177vs, 1063s, 1009s, 974m, 910m, 738s, 700s. 1H NMR 
(CDCl3): δ 7.64–7.62 (m, 2H, HC(arom)); 7.60–7.58 (m, 2H, HC(arom)); 7.53–7.49 (m, 3H, 
HC(arom)); 7.44–7.35 (m, 5H, HC(arom)); 7.29–7.25 (m, 2H, HC(arom)); 7.24–7.20 (m, 1H, 
HC(arom)); 4.83, 4.50 (AB, JAB = 9.6, 2H, H2C). 13C NMR (CDCl3): δ 157.3, 138.5, 134.5, 
133.6, 130.2, 130.2, 129.1, 128.9, 128.3, 128.2, 127.3, 127.1, 126.9, 125.9, 121.8 (15 
CH(arom), 3 C(arom), 3 C(imid)); 125.3 (q, 1JC,F = 280.9, CF3); 92.0 (q, 2JC,F = 30.5, CCF3); 
51.2 (CH2). 19F NMR (CDCl3): δ –80.7. HR-ESI-MS: 407.13492 (calcd 407.13657 for 
C24H18ON2F3, [M+H]+). [α]D25 = +48 (c 1.0, CH2Cl2). 
 
(R)-2,5,6-Triphenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole ((R)-8a). Yield: 
0.327 g (83%). Colorless oil. IR (film): ν 3061br.m, 2926m, 1606s, 1589s, 1572s, 1500s, 
1443s, 1340s, 1305s, 1197vs, 1174vs, 1063s, 1009s, 974s, 915m, 738s, 699s. 1H NMR 
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(CDCl3): δ 7.64–7.61 (m, 2H, HC(arom)); 7.60–7.57 (m, 2H, HC(arom)); 7.53–7.50 (m, 3H, 
HC(arom)); 7.43–7.35 (m, 5H, HC(arom)); 7.29–7.25 (m, 2H, HC(arom)); 7.23–7.20 (m, 1H, 
HC(arom)); 4.83, 4.50 (AB, JAB = 9.6, 2H, H2C). 13C NMR (CDCl3): δ 157.3, 138.5, 134.5, 
133.6, 130.2, 130.2, 129.1, 128.9, 128.3, 128.2, 127.3, 127.1, 126.9, 125.9, 121.8 (15 
CH(arom), 3 C(arom), 3 C(imid)); 125.3 (q, 1JC,F = 282.5, CF3); 92.0 (q, 2JC,F = 30.5, CCF3); 
51.2 (CH2). 19F NMR (CDCl3): δ –80.7. HR-ESI-MS: 407.13519 (calcd 407.13657 for 
C24H18ON2F3, [M+H]+). [α]D25 = –50 (c 1.0, CH2Cl2). 
 
2-(4-Methoxyphenyl)-5,6-diphenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole 
((RS)-8b). Yield: 0.349 g (80%). Colorless crystals. Mp. 202–204 °C. IR (KBr): ν 3432br.m, 
2967w, 2844w, 1606s, 1588s, 1572s, 1518s, 1500s, 1443m, 1346m, 1310s, 1251s, 1175vs, 
1063m, 1015m, 995s, 832m, 757m, 702s. 1H NMR (CDCl3): δ 7.61–7.58 (m, 2H, HC(arom)); 
7.55–7.52 (m, 2H, HC(arom)); 7.43–7.35 (m, 5H, HC(arom)); 7.29–7.25 (m, 2H, HC(arom)); 
7.24–7.19 (m, 1H, HC(arom)); 7.03–6.99 (m, 2H, HC(arom)); 4.79, 4.47 (AB, JAB = 9.6, 2H, 
H2C); 3.86 (s, 3H, H3C). 13C NMR (CDCl3): δ 160.9, 157.3, 138.5, 134.5, 130.2, 129.1, 128.3, 
128.2, 128.1, 127.4, 127.1, 126.9, 125.4, 121.8, 114.4 (14 CH(arom), 4 C(arom), 3 C(imid)); 
123.4 (q, 1JC,F = 282.4, CF3); 92.0 (q, 2JC,F = 31.4, CCF3); 55.4 (CH3); 51.2 (CH2). 19F NMR 
(CDCl3): δ –81.0. HR-ESI-MS: 437.14628 (calcd 437.14714 for C25H20O2N2F3, [M+H]+). 
 
(S)-2-(4-Methoxyphenyl)-5,6-diphenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-
b]oxazole ((S)-8b). Yield: 0.371 g (85%). Colorless oil. IR (film): ν 3061br.m, 1606s, 1588s, 
1572s, 1517s, 1501s, 1443s, 1307s, 1254s, 1178vs, 1020s, 1001s, 974m, 831s, 735s, 700s. 1H 
NMR (CDCl3): δ 7.60–7.57 (m, 2H, HC(arom)); 7.55–7.53 (m, 2H, HC(arom)); 7.43–7.35 
(m, 5H, HC(arom)); 7.29–7.25 (m, 2H, HC(arom)); 7.23–7.20 (m, 1H, HC(arom)); 7.03–7.00 
(m, 2H, HC(arom)); 4.79, 4.47 (AB, JAB = 9.6, 2H, H2C); 3.86 (s, 3H, H3C). 13C NMR 
(CDCl3): δ 160.9, 157.3, 138.5, 134.5, 130.2, 129.1, 128.3, 128.2, 128.1, 127.4, 127.1, 126.9, 
125.4, 121.8, 114.4 (14 CH(arom), 4 C(arom), 3 C(imid)); 125.3 (q, 1JC,F = 279.8, CF3); 92.0 
(q, 2JC,F = 31.1, CCF3); 55.4 (CH3); 51.2 (CH2). 19F NMR (CDCl3): δ –81.0. HR-ESI-MS: 
437.14621 (calcd 437.14714 for C25H20O2N2F3, [M+H]+). [α]D25 = +36 (c 1.0, CH2Cl2). 
 
(R)-2-(4-Methoxyphenyl)-5,6-diphenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-
b]oxazole ((R)-8b). Yield: 0.375 g (86%). Colorless crystals. Mp. 120–122 °C. IR (KBr): ν 
3424br.w, 3058w, 2842w, 1606s, 1592s, 1573s, 1517s, 1501s, 1443m, 1341m, 1305s, 1253s, 
	   13	  
1172vs, 1019s, 1000s, 974m, 829m, 770m, 701s. 1H NMR (CDCl3): δ 7.61–7.58 (m, 2H, 
HC(arom)); 7.55–7.52 (m, 2H, HC(arom)); 7.43–7.35 (m, 5H, HC(arom)); 7.29–7.25 (m, 2H, 
HC(arom)); 7.23–7.20 (m, 1H, HC(arom)); 7.03–6.99 (m, 2H, HC(arom)); 4.79, 4.47 (AB, 
JAB = 10.2, 2H, H2C); 3.86 (s, 3H, H3C). 13C NMR (CDCl3): δ 160.9, 157.3, 138.5, 134.5, 
130.2, 129.1, 128.3, 128.2, 128.1, 127.4, 127.1, 126.9, 125.4, 121.8, 114.4 (14 CH(arom), 4 
C(arom), 3 C(imid)); 123.4 (q, 1JC,F = 282.8, CF3); 92.0 (q, 2JC,F = 31.5, CCF3); 55.4 (CH3); 
51.2 (CH2). 19F NMR (CDCl3): δ –81.0. HR-ESI-MS: 437.14613 (calcd 437.14714 for 
C25H20O2N2F3, [M+H]+). [α]D25 = –39 (c 1.0, CH2Cl2). 
 
(S)-(4-Methoxyphenyl)-5,6-dimethyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole 
((S)-8c). Yield: 0.156 g (50%). Colorless oil. IR (film): ν 3294br.w, 2933w, 2838w, 1774w, 
1730m, 1692m, 1613m, 1515m, 1302m, 1258m, 1176m, 1030m, 834m, 732m. 1H NMR 
(CDCl3): δ 7.41–7.37 (m, 2H, HC(arom)); 6.91–6.87 (m, 2H, HC(arom)); 4.53, 4.20 (AB, JAB 
= 9.5, 2H, H2C); 3.75 (s, 3H, H3C); 1.98 (s, 6H, 2 H3C). 13C NMR (CDCl3): δ 160.8, 155.7, 
133.8, 127.4, 115.2, 114.4, 114.2 (4 CH(arom), 2 C(arom), 3 C(imid)); 125.0 (q, 1JC,F = 285.2, 
CF3); 91.6 (q, 2JC,F = 31.3, CCF3); 55.4 (CH3); 50.2 (CH2); 13.1 (CH3); 8.7 (CH3). 19F NMR 
(CDCl3): δ –80.9. HR-ESI-MS: 313.11573 (calcd 313.11584 for C15H16O2N2F3, [M+H]+). 
[α]D
25 = +18 (c 1.0, CH2Cl2). 
 
(R)-2-(4-Methoxyphenyl)-5,6-dimethyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-
b]oxazole ((R)-8c). Yield: 0.152 g (49%). Colorless oil. IR (film): ν 3269br.w, 2923w, 
2841w, 1777w, 1717m, 1682m, 1616m, 1518m, 1306m, 1261m, 1173m, 1030m, 831m, 
736w. 1H NMR (CDCl3): δ 7.40–7.37 (m, 2H, HC(arom)); 6.90–6.87 (m, 2H, HC(arom)); 
4.53, 4.20 (AB, JAB = 9.5, 2H, H2C); 3.75 (s, 3H, H3C); 1.98 (s, 6H, 2 H3C). 13C NMR 
(CDCl3): δ 160.8, 155.6, 133.8, 127.4, 115.2, 114.5, 114.1 (4 CH(arom), 2 C(arom), 3 
C(imid)); 125.1 (q, 1JC,F = 285.2, CF3); 91.6 (q, 2JC,F = 31.4, CCF3); 55.4 (CH3); 50.2 (CH2); 
13.1 (CH3); 8.7 (CH3). 19F NMR (CDCl3): δ –80.9. HR-ESI-MS: 313.11591 (calcd 313.11584 
for C15H16O2N2F3, [M+H]+). [α]D25 = –20 (c 1.0, CH2Cl2). 
 
(S)-2-(4-Methoxyphenyl)-6-methyl-5-phenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-
b]oxazole ((S)-8d). Yield: 0.295 g (79%). Colorless oil. IR (film): ν 3296br.w, 3063w, 
2926w, 2856w, 1783m, 1713m, 1654m, 1593m, 1450m, 1308m, 1178m, 1011m, 739m, 
702w. 1H NMR (CDCl3): δ 7.42–7.39 (m, 2H, HC(arom)); 7.36–7.32 (m, 2H, HC(arom)); 
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7.23–7.19 (m, 3H, HC(arom)); 6.91–6.87 (m, 2H, HC(arom)); 4.70, 4.37 (AB, JAB = 9.8, 2H, 
H2C); 3.75 (s, 3H, H3C); 2.22 (s, 3H, H3C). 13C NMR (CDCl3): δ 160.9, 157.1, 136.3, 130.2, 
128.9, 127.4, 126.8, 126.7, 125.5, 121.6, 114.3 (9 CH(arom), 3 C(arom)), 3 (C(imid)); 123.4 
(q, 1JC,F = 282.3, CF3); 91.9 (q, 2JC,F = 31.3, CCF3); 55.4 (CH2); 51.6 (CH3); 14.6 (CH3). 19F 
NMR (CDCl3): δ –81.6. HR-ESI-MS: 375.13269 (calcd 375.13149 for C20H18O2N2F3, 
[M+H]+). [α]D25 = +29 (c 1.0, CH2Cl2). 
 
(R)-2-(4-Methoxyphenyl)-6-methyl-5-phenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-
b]oxazole ((R)-8d). Yield: 0.299 g (80%). Colorless oil. IR (film): ν 3292br.w, 3063w, 
2926w, 2856w, 1780w, 1716w, 1593w, 1450w, 1308w, 1177w, 1011w, 738w, 700w. 1H 
NMR (CDCl3): δ 7.42–7.39 (m, 2H, HC(arom)); 7.36–7.32 (m, 2H, HC(arom)); 7.23–7.18 
(m, 3H, HC(arom)); 6.91–6.87 (m, 2H, HC(arom)); 4.70, 4.37 (AB, JAB = 9.8, 2H, H2C); 3.76 
(s, 3H, H3C); 2.22 (s, 3H, H3C). 13C NMR (CDCl3): δ 160.9, 157.1, 136.2, 130.2, 128.9, 
127.4, 126.9, 126.7, 125.5, 121.6, 114.3 (9 CH(arom), 3 C(arom)), 3 (C(imid)); 123.4 (q, 1JC,F 
= 282.4, CF3); 91.9 (q, 2JC,F = 32.1, CCF3); 55.4 (CH2); 51.6 (OCH3); 14.5 (CH3). 19F NMR 
(CDCl3): δ –81.6. HR-ESI-MS: 375.13295 (calcd 375.13149 for C20H18O2N2F3, [M+H]+). 
[α]D
25 = –30 (c 1.0, CH2Cl2). 
 
(S)-5-Methyl-2-phenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole-6-carboxylic 
acid phenylamide ((S)-8e). Yield: 0.313 g (81%). Colorless crystals. Mp. 148–150 °C. IR 
(KBr): ν 3378w, 3361w, 1697s, 1614s, 1594s, 1523s, 1491s, 1441s, 1380m, 1302m, 1210s, 
1173s, 1065m, 1007m, 904w, 761m, 698m. 1H NMR (CDCl3): δ 8.65 (s, 1H, NH); 7.58–7.55 
(m, 2H, HC(arom)); 7.49–7.46 (m, 2H, HC(arom)); 7.43–7.40 (m, 3H, HC(arom)); 7.26–7.22 
(m, 2H, HC(arom)); 7.02–6.97 (m, 1H, HC(arom)); 4.69, 4.37 (AB, JAB = 10.2, 2H, H2C); 
2.48 (s, 3H, H3C). 13C NMR (CDCl3): δ 154.1 (C=O); 161.3, 138.2, 133.0, 131.1, 130.5, 
129.1, 128.9, 127.3, 125.8, 123.7, 119.5 (10 CH(arom), 2 C(arom), 3 C(imid)); 123.2 (q, 1JC,F 
= 282.2, CF3); 92.4 (q, 2JC,F = 31.4, CCF3); 49.7 (CH2); 10.2 (CH3). 19F NMR (CDCl3): δ –
80.9. HR-ESI-MS: 388.12610 (calcd 388.12674 for C20H17O2N3F3, [M+H]+). [α]D25 = +42 (c 
0.1, CH2Cl2). 
 
(R)-5-Methyl-2-phenyl-2-trifluoromethyl-2,3-dihydroimidazo[2,1-b]oxazole-6-carboxylic 
acid phenylamide ((R)-8e). Yield: 0.321 g (83%). Colorless crystals. Mp. 140–142 °C. IR 
(KBr): ν 3378m, 3361m, 1697s, 1613s, 1594s, 1523s, 1492s, 1441s, 1380m, 1303s, 1210s, 
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1174s, 1065m, 1007m, 904w, 792m, 761s, 698s. 1H NMR (CDCl3): δ 8.76 (s, 1H, NH); 7.67–
7.65 (m, 2H, HC(arom)); 7.60–7.57 (m, 2H, HC(arom)); 7.53–7.51 (m, 3H, HC(arom)); 7.36–
7.32 (m, 2H, HC(arom)); 7.12–7.08 (m, 1H, HC(arom)); 4.79, 4.47 (AB, JAB = 10.2, 2H, 
H2C); 2.59 (s, 3H, H3C). 13C NMR (CDCl3): δ 154.1 (C=O); 161.3, 138.2, 133.0, 131.1, 
130.5, 129.1, 128.9, 127.3, 125.8, 123.7, 119.5 (10 CH(arom), 2 C(arom), 3 C(imid)); 123.2 
(q, 1JC,F = 283.1, CF3); 92.4 (q, 2JC,F = 31.6, CCF3); 49.7 (CH2); 10.2 (CH3). 19F NMR 
(CDCl3): δ –80.9. HR-ESI-MS: 388.12610 (calcd 388.12674 for C20H17O2N3F3, [M+H]+). 
[α]D
25 = –41 (c 1.0, CH2Cl2). 
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